UMB 425 is being called a breakthrough in the development of therapeutics to treat chronic pain, acts on two different opioid receptors with diminished tolerance over time and no obvious toxic effects.
A team of researchers led by Andrew Coop, PhD, professor and chair of the Department of Pharmaceutical Sciences (PSC) at the University of Maryland School of Pharmacy (UMSOP), has developed a new opioid drug that shows great potential to advance treatment and improve quality of life for individuals living with chronic pain. Spotlighted in a recent issue of ACS Chemical Neuroscience, the compound, known as UMB 425, is as strong as morphine, but displays diminished tolerance over time with no obvious toxic effects.
“UMB 425 is a breakthrough in the development of therapeutics to treat chronic pain,” says Coop. “Unlike other drugs developed to act on only one biological target, UMB 425 acts on two different opioid receptors in the body. When activated at the same time, these receptors work together to provide pain relief and slow the body’s development of tolerance to the drug. This diminished tolerance allows a lower dose of the opioid to be administered for a longer time period, while still achieving the same level of pain relief.”
For individuals living with chronic pain, either as a result of injury or disease such as arthritis, opioids are the standard treatment. But as the dosage increases to offset the body’s tolerance to their effects, opioids cause a number of adverse effects, including constipation, nausea, drowsiness, and dizziness. The unique dual-profile of UMB 425 – made possible through Coop’s collaborations with Alexander MacKerell, PhD, professor in PSC and director of the School’s Computer Aided Drug Design Center, and Maureen Kane, PhD, assistant professor in PSC and co-director of the School’s Mass Spectrometry Facility – provides both pain relief as well as diminished tolerance in one drug.
“Historically, medicinal chemists have developed drugs aimed at only one biological target,” says Coop. “However, two drugs administered together have the potential to metabolize differently in different individuals, as well as affect patients’ adherence to both drugs. A single compound that is able to provide both pain relief and diminished tolerance has the advantage of a defined ratio that we can optimize to ensure patients receive the maximum pain relief, while experiencing minimum adverse effects.”
Coop and his team conducted several in vitro and in vivo studies to determine the drug’s effectiveness in alleviating pain and diminishing tolerance over time. If future research and clinical trials are successful, UMB 425 could have a significant impact on the treatment and quality of life for individuals living with chronic pain.
“The clinical implication of this research has the potential to be tremendous,” says Mary Lynn McPherson, PharmD, BCPS, CPE, professor and vice chair for academic affairs in the Department of Pharmacy Practice and Science, and an international authority in the fields of pain management and palliative care. “If clinicians can prescribe lower doses of opioids, they will not have to raise a patient’s dose because of tolerance to the analgesic effects. Using lower doses will result in less severe adverse effects for the patient, both short-term effects such as nausea and constipation, as well as long-term adverse effects on the endocrine and immunologic systems. This would be a highly significant advance in pain management.”
The Latest Bing News on:
- Dr Wayne Jonas Discusses Unmet Needs for Acute and Chronic Painon December 4, 2020 at 5:04 pm
Wayne Jonas, MD, executive director of Samueli Integrative Health Programs at H&S Ventures, discusses the unmet needs that still exist for patients with chronic and acute pain.
- 10 Gifts For People With Chronic Pain and Sore Muscleson December 3, 2020 at 11:18 pm
What exactly do you get for a chronic pain sufferer? With a range of prices to suit your budget, we've put together a list of pain-relieving products that are on the market for people with chronic ...
- When Chronic Pain Threatens to Halt Your Careeron December 3, 2020 at 9:30 pm
I want to quit my job. I thoroughly enjoy it, but I can’t stay. I’m working in the field I’m interested in. I’m in the process of getting a master’s degree in this field. I feel purposeful and content ...
- Misguided federal regulations are likely to cause more pain in people already living with iton December 2, 2020 at 6:59 am
One group that is paying the price for it, but shouldn’t be, are people who live with chronic pain conditions. The opioid epidemic was initially fueled by the misuse of prescription opioids that ...
- Fibromyalgia during COVID-19, anxiety and painon November 30, 2020 at 7:40 pm
Researchers in the UK hypothesized that this anxiety would be associated with increased pain in chronic pain patients diagnosed with fibromyalgia (FM). Fibromyalgia affects around 2% of the world ...
- Managing Chronic Painon November 30, 2020 at 7:43 am
Dr. Hui Kang with Northwest Anesthesiology and Pain Services explains how they can help you live pain free from various causes of chronic pain.
- Explore a few alternative ways to alleviate chronic painon November 28, 2020 at 10:57 am
According to the Centers for Disease Control and Prevention, an estimated 20.4% of U.S. adults had chronic pain, and 8% percent of U.S. adults had high-impact chronic pain in 2016. Chronic pain ...
- $150+ Billion Chronic Pain Treatment Market - Global Industry Analysis and Growth Forecast to 2030 - ResearchAndMarkets.comon November 27, 2020 at 10:59 am
The global chronic pain treatment market is predicted to progress at a CAGR of 6.5% from 2020 to 2030 and generate a revenue of $151.7 billion in 2030. The factors fueling the expansion of the market ...
- $150+ Billion Chronic Pain Treatment Market - Global Industry Analysis and Growth Forecast to 2030 - ResearchAndMarkets.comon November 27, 2020 at 10:39 am
The "Chronic Pain Treatment Market Research Report: By Product, Indication, Application, Distribution Channel, End User - Global Industry Analysis and Growth Forecast to 2030" report has been ...
- Tarantula Toxins Provide Insights to Treating Chronic Painon November 24, 2020 at 4:00 am
Studying tarantula toxins has helped researchers understand how to control chronic pain and may provide guidance to design better analgesic drugs.
The Latest Google Headlines on:
The Latest Bing News on:
- Minth Group Ltd.on November 26, 2020 at 4:00 pm
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
- Merck’s COVID-19 coalition grows with Oncoimmune acquisitionon November 22, 2020 at 4:00 pm
With its acquisition of privately held Oncoimmune Ltd. for an up-front $425 million in cash, Merck & Co. Inc. ups its COVID-19 game with CD24Fc, a recombinant fusion protein targeting the innate ...
- MicroStrategy Announces Third Quarter 2020 Financial Resultson October 27, 2020 at 2:08 pm
The purchase of $425 million of bitcoin during the quarter offers the possibility of greater return potential for investors than holding such balances in cash and has increased the overall visibility ...
- Trains Between Ambala Cantonment and Sultanpur Junction • List of Ambala Cantonment - Sultanpur Junction Trainson April 13, 2018 at 8:02 pm
Find all trains running between Sultanpur Junction (SLN) and Ambala Cantonment (UMB). This page gives train name, train number and timing of trains operating on the Sultanpur Junction - Ambala ...
- Trains Between Sultanpur Junction and Ambala Cantonment • List of Sultanpur Junction - Ambala Cantonment Trainson April 11, 2018 at 7:10 pm
Find all trains running between Ambala Cantonment (UMB) and Sultanpur Junction (SLN). This page gives train name, train number and timing of trains operating on the Ambala Cantonment - Sultanpur ...